Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
16.07. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
JIN MEDICAL INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
16.07. | Jin Medical International Ltd.: Jin Medical Launches Production at Plant No. 3, Accelerating Global Delivery from the Chuzhou Manufacturing Facility | 1 | GlobeNewswire (USA) | ||
24.06. | Jin Medical International ernennt Dr. James Jiayuan Tong zum unabhängigen Direktor | 6 | Investing.com Deutsch | ||
24.06. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
17.06. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
06.05. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
06.05. | Jin Medical International Ltd. - Nasdaq Minimum Bid Price Non-Compliance | 46 | GlobeNewswire (Europe) | Changzhou City, China, May 06, 2025 (GLOBE NEWSWIRE) -- Jin Medical International Ltd. (NASDAQ: ZJYL) (the "Company") today announced that on May 2, 2025, it received a deficiency letter (the "Notice")... ► Artikel lesen | |
25.04. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SERNOVA BIOTHERAPEUTICS | 0,119 | -4,80 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes | LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics ("Sernova") (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals... ► Artikel lesen | |
PLUS THERAPEUTICS | 0,500 | -5,45 % | Plus Therapeutics Inc.: Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT | HOUSTON, July 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 0,808 | +0,87 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer | SEATTLE, July 29, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced... ► Artikel lesen | |
PING AN HEALTHCARE | 1,320 | +11,07 % | HSI Down 347 pts; HSTI Down 153 pts; LI AUTO Down over 12%; PETROCHINA, CSPC PHARMA, JD HEALTH, WUXI APPTEC, PA GOODDOCTOR Hit New Highs; Market Turnover Rises | ||
MOUNTAIN VALLEY MD | 0,018 | +24,32 % | Mountain Valley MD Holdings Inc: Mountain Valley appoints Batchelor as director | ||
CO-DIAGNOSTICS | 0,242 | +7,08 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
CYTOSORBENTS | 0,763 | 0,00 % | Cytosorbents Corp: CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR | PRINCETON, N.J., July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions... ► Artikel lesen | |
VERU | 0,443 | +3,41 % | VERU INC. - 8-K, Current Report | ||
AMBU | 13,300 | -1,63 % | Ambu A/S: Interim Report For Q2 2024/25 And The Half-year | 7.5.2025 07:00:01 CEST | Ambu A/S |
Half Year financial report
In the second quarter of the 2024/25 financial year, Ambu delivered 11.7% organic revenue growth and a 14.4% EBIT margin before special... ► Artikel lesen | |
TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China | Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest... ► Artikel lesen | |
VOLITIONRX | 0,749 | 0,00 % | VolitionRx - Nu.Q advances in lung cancer management | Despite rapid advancements in cancer treatments, effective diagnostics for early screening and disease monitoring continue to be an unmet need. This is felt acutely in lung cancer, which is the leading... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 49,730 | +2,47 % | Chinas Griff nach dem Rohstoffmarkt wackelt - und dieses Unternehmen steht bereit, die Lücke zu füllen! | ||
FRESENIUS | 42,630 | +0,78 % | Fresenius erhält EU-Zulassung für zwei Denosumab-Biosimilars | DJ Fresenius erhält EU-Zulassung für zwei Denosumab-Biosimilars
DOW JONES--Fresenius hat nach eigener Aussage die Zulassung der EU-Kommission für zwei Biosimilars in Europa erhalten.
Wie Fresenius... ► Artikel lesen | |
GERRESHEIMER | 44,620 | -3,21 % | Evotec, Gerresheimer, Hugo Boss, Puma, Renk Group, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 45,090 | -0,38 % | Fitch bestätigt Fresenius Medical Care mit "BBB-" - Ausblick stabil | DJ Fitch bestätigt Fresenius Medical Care mit "BBB-" - Ausblick stabil
DOW JONES--Fitch Ratings hat die Langfrist-Ratings von Fresenius Medical Care (FMC) mit "BBB-" bestätigt. Der Rating-Ausblick... ► Artikel lesen |